Influence of Body Weight and Composition on Immune Recovery
NCT ID: NCT04737681
Last Updated: 2022-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2020-09-01
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Obesity in Military Communities - Fit4Duty
NCT02679937
Army Training at High Intensity Study
NCT02407093
Social and Financial Incentives to Increase Physical Activity Among Overweight and Obese Veterans
NCT03563027
Redefining BMI: The Body, Mind, and Inflammation Trial
NCT06532747
Preventing Obesity in Military Communities-Adolescents
NCT02671292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal BMI
BMI 18.5-24.9 kg/m2
body composition
This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
Obese BMI
BMI ≥ 30 kg/m2
body composition
This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
body composition
This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a Body Mass Index (BMI) in the range of 18.5 to \<25 kg/m2 and have a percent body fat by circumference measurements that meets the Army's max allowable body fat standards for individuals classified as "without obesity"; or have a BMI ≥ 30 kg/m2 and have a percent body fat by circumference measurements that exceeds the Army's max allowable body fat standards for individuals classified as "with obesity" (40).
* Have been weight stable (+/- 5 lbs.) for the past two months (not including temporary body weight fluctuations due to menstrual cycle) and agree not to attempt to lose or gain weight for the duration of the study;
* Participate in 120-300 mins of aerobic exercise over the course of at least 3 days per week as indicated by self-report data and confirmed during the study via actigraphy (i.e., consistent with the self-reported exercise habits of a majority of active duty military personnel) (1, 41)
* Are willing to participate in all study procedures and comply with all study instruction.
* Females must have normal menstrual cycles between 26-32 days in duration; 5 menstrual cycles within the past 6 months; or able to provide documentation of oral/hormonal contraceptive use which contains low-dose estrogen/progesterone to maintain continuous levels throughout the 28-day cycle (i.e., no placebos)
* Pass a general medical clearance.
Exclusion Criteria
* experienced more than a \~5 lbs. weight gain or loss in the last month than is not transient (e.g., menstrual).
* participate in more than 300 minutes of aerobic exercise per week as indicated by self-report data and confirmed during the study via actigraphy (i.e., consistent with self-reported exercise habits of \~20% of active duty military personnel) (1, 41).
* are habitually taking nonsteroidal anti-inflammatory drugs (e.g., Advil), aspirin, lipid-lowering drugs, corticosteroids or immunosuppressants (e.g. Humira);
* are immune-compromised (e.g., chemotherapy or radiation treatment);
* are suffering from an autoimmune disease (e.g., lupus);
* recovering from a surgery within the past 6 months;
* Current doctor-diagnosed and/or treated diabetes, hypertension or dyslipidemia
* are suffering from sleep apnea;
* smoke, dip, chew or vape tobacco or nicotine-containing products.
* regularly (more than 2 days per week) sleep less than 7 hours or more than 9 hours per night; or, take a nap 3 or more days per week.
* Pregnant or lactating
* problems with blood clotting (in the subset of participants receiving muscle biopsies only)
* allergy to lidocaine (in the subset of participants receiving biopsies only)
Females Only:
• Have abnormal menstrual cycles (not between 26-32 days in duration; or not 5-6 menstrual cycles within the past 6 month) or those that have had an intrauterine device (IUD) placed with the last month or removed within the past 3 months.
18 Years
39 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Army Research Institute of Environmental Medicine
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
U.S. Army Research Institute of Environmental Medicine
Natick, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-26HC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.